IPHA
Innate Pharma

1,489
Loading...
Loading...
News
all
press releases
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Szary Syndrome
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Business Wire·7mo ago
News Placeholder
More News
News Placeholder
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety...
Business Wire·8mo ago
News Placeholder
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate...
Business Wire·8mo ago
News Placeholder
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General...
Business Wire·8mo ago
News Placeholder
Innate Pharma Announces Transformative Strategy to Accelerate Growth
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its updated strategy for company growth. This comprehensive plan is anchored in three key...
Business Wire·8mo ago
News Placeholder
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced new data highlighting the quality-of-life improvements observed in patients with...
Business Wire·9mo ago
News Placeholder
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), together with the Institute for Follicular Lymphoma (IFLI) today announced that they have entered into...
Business Wire·10mo ago
News Placeholder
Innate Pharma Releases Its 2025 Financial Calendar
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today released its 2025 financial calendar: March 27, 2025: Publication of 2024 financial statements May...
Business Wire·10mo ago
News Placeholder
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the publication in Science Immunology of preclinical data demonstrating the potential of...
Business Wire·10mo ago
News Placeholder
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2024. 'Im honored...
Business Wire·10mo ago

Latest IPHA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.